Company Description
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.
Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine.
It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
The company was headquartered in 1996 and is based in Silver Spring, Maryland.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 17, 1999 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,400 |
| CEO | Martine Rothblatt |
Contact Details
Address: 1000 Spring Street Silver Spring, Maryland 20910 United States | |
| Phone | 301 608 9292 |
| Website | unither.com |
Stock Details
| Ticker Symbol | UTHR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001082554 |
| CUSIP Number | 91307C102 |
| ISIN Number | US91307C1027 |
| Employer ID | 52-1984749 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman and Chief Executive Officer |
| Michael I. Benkowitz | President and Chief Operating Officer |
| James C. Edgemond | Chief Financial Officer and Treasurer |
| Paul A. Mahon J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Harrison Silvers | Manager of Investor Relations |
| Holly Hobson | Associate Vice President of Human Resources |
| Kevin T. Gray | Senior Vice President of Strategic Operations and Logistics |
| Patrick Poisson | Executive Vice President of Technical Operations |
| Dr. Leigh Peterson | Executive Vice President of Product Development and Xenotransplantation |
| Gil Golden | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 144 | Filing |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 19, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |
| Feb 10, 2026 | SCHEDULE 13G | Filing |